Berndt Modig Sells 2,291 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) CEO Berndt Modig sold 2,291 shares of the stock in a transaction on Monday, September 14th. The stock was sold at an average price of $39.40, for a total value of $90,265.40. Following the transaction, the chief executive officer owned 128,334 shares of the company’s stock, valued at approximately $5,056,359.60. This represents a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Berndt Modig also recently made the following trade(s):

• On Friday, August 14th, Berndt Modig sold 2,292 shares of Pharvaris stock. The stock was sold at an average price of $34.77, for a total value of $79,692.84.

Pharvaris Price Performance

Shares of NASDAQ PHVS traded down $0.61 during midday trading on Tuesday, hitting $38.25. The company’s stock had a trading volume of 1,020,979 shares, compared to its average volume of 398,337. The business’s fifty day simple moving average is $35.20 and its two-hundred day simple moving average is $31.49. Pharvaris N.V. has a 1 year low of $20.65 and a 1 year high of $43.25. The firm has a market capitalization of $2.50 billion, a price-to-earnings ratio of -12.54 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Analysts anticipate that Pharvaris N.V. will post -3.12 EPS for the current fiscal year.

More Pharvaris News

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris’ shares have gained about 10% over the past month after Phase 3 results showed that the extended-release formulation of deucrictibant reduced hereditary angioedema attacks by 83%. The data support the company’s plans to pursue regulatory submissions in 2027 and strengthen the outlook for its lead drug candidate. PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
• Positive Sentiment: Analyst price-target expectations have improved. The reported consensus target was raised approximately 20% to $59.77, while RBC recently increased its target to $62 and maintained an outperform rating. The broader analyst view remains favorable, with a consensus “Moderate Buy” rating and an average target near $60. Pharvaris NV consensus price target raised 20.08% to $59.77
• Neutral Sentiment: Institutional ownership trends have been supportive, with investors including BlackRock and Alyeska Investment Group building positions. This may provide additional demand, although the purchases reflect earlier reporting periods rather than a new catalyst.
• Negative Sentiment: Several insiders recently sold shares. Director Anne Lesage sold 30,000 shares for approximately $1.15 million, while CEO Berndt Modig sold 2,291 shares for about $90,000 and President Peng Lu sold 15,000 shares for roughly $602,000. Lu’s transaction was made to cover tax withholding on vested equity awards, which reduces its negative signal, but the volume of insider selling could still weigh on sentiment. Insider Selling: Pharvaris Insider Sells 30,000 Shares

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Morgan Stanley raised their price objective on Pharvaris from $46.00 to $62.00 and gave the stock an “overweight” rating in a report on Wednesday, September 9th. New Street Research set a $60.00 target price on shares of Pharvaris in a report on Friday, August 14th. Rosenblatt Securities set a $60.00 price target on shares of Pharvaris in a research report on Wednesday, September 9th. Wells Fargo & Company increased their price target on shares of Pharvaris from $55.00 to $65.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research report on Friday, July 17th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $59.87.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Quantbot Technologies LP acquired a new position in Pharvaris in the second quarter valued at $41,000. CoreCap Advisors LLC purchased a new position in Pharvaris during the second quarter worth about $93,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in Pharvaris in the 4th quarter worth about $139,000. Public Employees Retirement System of Ohio purchased a new stake in Pharvaris in the 2nd quarter valued at about $196,000. Finally, Algert Global LLC purchased a new stake in Pharvaris in the 2nd quarter valued at about $238,000.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.